Translation-X

Translation-X will be at Bio-Europe 2024 in Stockholm from November 4-6. Please join us at the Swiss Pavillion, meet our co-founder, Özgür Genç, and learn about our recent progress in precision therapies for autism spectrum disorders. #biotech #autism #autismspectrumdisorders #precisionmedicine #neuroscience

CHF 150'000 for Translation-X to address an unmet medical need in autism spectrum disorder. Congratulations to the excellent team of founders: Peter Scheiffele, Özgür Genç, and Guido Koch. https://lnkd.in/deuE6VRy About: Translation-X is pioneering an innovative therapeutic strategy to address autism spectrum disorders (ASD), focusing on the role of selective mRNA translation in its pathophysiology. Recognizing that impaired mRNA translation is a key factor in a specific subgroup of ASD cases, the company is targeting Map-kinase interacting kinases (MNK) as a potential drug target. By inhibiting MNK activity, Translation-X seeks to normalize mRNA translation and improve neural function, offering a groundbreaking treatment that directly tackles the genetic causes of this form of autism, thus addressing a critical gap in available therapies for core ASD symptoms. #SwissStartups #VentureKick 

Kicking innovation for safe energy transfer to life-saving implants, autism spectrum disorders treatment, and solar cells on railway tracks: COSKIN, Translation-X, and Sun-Ways advance to next stage of Venture Kick, receiving CHF 40,000 each. Congratulations to the teams of founders Andreas Kourouklis, Baptiste Danichert, Joseph Scuderi, Peter Scheiffele, Özgür Genç, and Guido Koch. https://lnkd.in/ezPjt696 COSKIN: Safe energy and data transfer in heart failure https://lnkd.in/eJuxPiQv Translation-X: Targeting selective mRNA translation for a precision medicine approach in autism spectrum disorders https://lnkd.in/eJ6NYfaG Sun-Ways: the new solar tracks https://lnkd.in/e5Z6mZ-V #SwissStartups #VentureKick

Translational Academic Talk III by Özgür Genç (Translation-X, Biozentrum, University of Basel, University of Basel) “Targeting selective mRNA translation for a precision medicine approach in autism" Register Now & Submit Abstracts: http://rnatx.ch Please help spread the word!

Kicking new innovation in CO2 capture, robotic material handling, pre-surgery decision-making, space mobility, infrastructure operation, and treatment of autism: Divea, Flink Robotics, Med4cast, peaKFlow, PAVE Space SA, and Translation-X win CHF 10,000 each, entering Venture Kick! Excited welcoming for the teams of entrepreneurs Mojtaba Chevalier, Kumar Varoon Agrawal, Karl Khalil, Moritz Geilinger, Simon Huber, Alexandre Lädermann, Philippe Collin, Patrick Denard, Frank Kolo, Heiner A. Weber, Serge Rovenne, Maximilien Renard, Tiago Salzmann, Yvan Bosshard, Rafael Monasterios, Peter Scheiffele, Özgür Genç, Guido Koch, Jérémy Marciacq, Pierre-Olivier Morin, Julie Böhning, Simon Both, and Lionel Isoz! https://lnkd.in/eJgsGtN8 Divea: Capturing CO2 at the source https://lnkd.in/e795jVyq Flink Robotics: Software intelligence for robotic material handling https://lnkd.in/eVjWJrTm Med4Cast: Revolutionizing pre-surgery decision-making by leveraging advanced AI diagnostics https://lnkd.in/eRuaSwhY PAVE Space SA: Revolutionize space mobility https://lnkd.in/eCJZHrfe peaKFlow: Turning Building Data into Actions https://lnkd.in/e6QCE_hg Translation-X: Targeting selective mRNA translation for a precision medicine approach in autism spectrum disorders https://lnkd.in/eJ6NYfaG #SwissStartups #VentureKick